Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target

TL;DR

Lipoprotein(a) is a genetic risk factor for heart disease, and new RNA-based therapies can significantly reduce it, turning it into a treatable target.

Contribution

The paper highlights RNA-targeted therapies as a novel approach to effectively lower Lp(a) and transform it from a biomarker to a therapeutic target.

Findings

Lp(a) contributes to cardiovascular disease through multiple harmful mechanisms.

RNA-targeted therapies can reduce Lp(a) by over 90%, surpassing traditional treatments.

Phase 3 trials will determine the clinical value of Lp(a) screening and treatment.

Abstract

What are the main findings?
Lipoprotein(a) [Lp(a)] acts as a distinct, genetically determined driver of cardiovascular disease by integrating pro-atherogenic, pro-inflammatory, and pro-thrombotic mechanisms.Emerging RNA-targeted platforms, such as antisense oligonucleotides and siRNAs, can achieve potent and durable Lp(a) reductions of over 90%, overcoming the limitations of conventional therapies.

Lipoprotein(a) [Lp(a)] acts as a distinct, genetically determined driver of cardiovascular disease by integrating pro-atherogenic, pro-inflammatory, and pro-thrombotic mechanisms.

Emerging RNA-targeted platforms, such as antisense oligonucleotides and siRNAs, can achieve potent and durable Lp(a) reductions of over 90%, overcoming the limitations of conventional therapies.

What are the implications of the main findings?
The development of potent Lp(a)-lowering therapeutics facilitates a transition from identifying Lp(a) as a risk marker to utilizing it as a specific therapeutic target.Ongoing Phase 3 clinical trials will define the clinical necessity of routine Lp(a) screening and the potential for mitigating residual risk in patients with ASCVD and aortic stenosis.

The development of potent Lp(a)-lowering therapeutics facilitates a transition from identifying Lp(a) as a risk marker to utilizing it as a specific therapeutic target.

Ongoing Phase 3 clinical trials will define the clinical necessity of routine Lp(a) screening and the potential for mitigating residual risk in patients with ASCVD and aortic stenosis.

Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Although elevated Lp(a) affects approximately 20% of the global population, specific pharmacological options have long been unavailable, leaving a major gap in residual risk management. This review synthesizes current understanding of Lp(a) molecular architecture, genetics, and metabolism, and integrates mechanistic evidence linking Lp(a) to pro-atherogenic, pro-inflammatory, and pro-thrombotic pathways. We summarize epidemiological and genetic data associating Lp(a) with a broad spectrum of cardiovascular outcomes and discuss current clinical guidelines on screening and risk stratification. Furthermore, we provide an up-to-date overview of the emerging therapeutic landscape, including RNA-targeted therapies and novel oral small molecules. With pivotal phase 3 outcome trials nearing completion, the field is transitioning from viewing Lp(a) as an untreatable biomarker to an actionable therapeutic target, with important implications for precision cardiovascular prevention.

Figures